Impact of tirofiban on the progression of neurological deterioration in individuals with acute ischemic stroke

According to a recent study, tirofiban was found to reduce the likelihood of early neurological deterioration in patients with noncardioembolic stroke who sought medical attention within 24 hours of experiencing symptoms. The use of tirofiban did not result in an increased risk of symptomatic intracerebral hemorrhage or systemic bleeding. This study’s results were published in the journal, JAMA neurology.

In this multicenter, randomized clinical trial, a total of 425 patients were enrolled. Among them, 213 patients received intravenous tirofiban while the remaining 212 patients were given oral aspirin for a duration of 72 hours. All patients then received oral aspirin. The primary efficacy outcome of the study was early neurological deterioration defined as an increase of 4 or more points in the NIHSS score within 72 hours after randomization. Additionally, the primary safety outcome assessed was symptomatic intracerebral hemorrhage occurring within the same 72-hour period after randomization.

9 patients from the tirofiban group and 28 patients from the aspirin group showed early neurological deterioration. Intracerebral hemorrhage was not observed in any of the patients belonging to the tirofiban group.

The above study demonstrated that tirofiban may lower the chances of early neurological deterioration in individuals with noncardioembolic stroke who received medical care within 24 hours of symptom onset. It reduced the risk of early neurological deterioration without raising the risk of symptomatic intracerebral hemorrhage or systemic bleeding.